Morquio Syndrome Therapy Market Size
The global Morquio syndrome therapy market was valued at approximately USD 102.18 million in 2025 and is projected to reach USD 216.23 million by 2035, expanding at a CAGR of 7.5% during the forecast period 2026–2035. The market is gaining momentum as growing awareness of rare genetic disorders, improved diagnostic capabilities, and advances in enzyme replacement therapy (ERT) support earlier diagnosis and treatment. Elosulfase alfa (Vimizim) remains a cornerstone of therapy for Morquio A syndrome, while ongoing research into gene therapy, substrate reduction therapy, and other innovative approaches is broadening the future treatment landscape.
The competitive opportunity is increasingly focused on disease-modifying therapies and improved long-term management of Morquio syndrome. Alongside pharmacological treatment, multidisciplinary care involving orthopedic interventions, physical therapy, respiratory support, and management of systemic complications continues to contribute to overall treatment demand. Increasing investment in rare-disease research and the development of therapies designed to address the underlying causes of Morquio syndrome are expected to create further opportunities through 2035. The market is therefore shifting toward earlier diagnosis, targeted enzyme replacement, innovative genetic approaches, and comprehensive patient management, supporting sustained growth in the global Morquio syndrome therapy market.
Morquio Syndrome Therapy Market Scope
| Metric | Details |
| Market Size in 2025 | USD 102.18 million |
| Market Size by 2035 | USD 216.23 million |
| CAGR | 7.50% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Type, Therapy, Route of Administration, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, Middle East & Africa |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
To Know More Insights - Download Sample
Morquio Syndrome Therapy Market Dynamics
Authorizations From Regulatory Bodies
The new approvals for the existing Morquio Syndrome therapy and increasing support from distinct regulatory authorities are expected to boost the global market growth during the forecast period. For instance, in June 2019, BioMarin Pharmaceutical Inc. obtained the National Medical Products Administration (NMPA) approval for its Vimizim (elosulfase alfa) in the treatment of individuals with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Vimizim is the first treatment in China approved for this condition.
Moreover, the NICE in March 2022, issued the conclusive draft guidance suggesting elosulfase alfa (also called Vimizin and made by BioMarin) for recurring usage in the NHS for the therapy of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Furthermore, the increasing research activities, growing awareness and plrevalence are also expected to boost the global market growth during the forecast period.
High Therapy Cost
The high cost of the therapy is expected to hamper the global market growth during the forecast period. For instance, the cost of elosulfase alfa in few nations is in beyween $2,080,000 to $6,240,000 per year, making it problematic for some health plans to afford it. Furthermore, the low treatment choices, low prevalence and high drug development costs are also expected to hamper the global market growth during the forecast period.
Morquio Syndrome Therapy Market Segment Analysis
The global morquio syndrome therapy market is segmented based on type, therapy, route of administration, distribution channel and region.
MPS IV Type A is Expected to Dominate Market
Owing to the increase in positive research investigation outcomes and high prevalence of MPS IV Type A than MPS IV Type B, it is estimated to dominate the global market during the forecast period. For instance, a team at the Universitat Autònoma de Barcelona (UAB), Spain, has developed the first rat model summarizing all disabling alterations encountered by individuals with Mucopolysaccharidosis type IVA, also termed Morquio A disease. The team has even created a gene therapy that fully restores the extreme whole-body alterations in the rat model after a single intravenous viral vector administration, opening the door to a prospective therapy that might be administered at young ages in patients detected with this rare disease, thereby averting bone malformations, osteoarthritic intricacies, and other life-threatening alterations.
Moreover, according to the National Organization for Rare Disorders, Inc. MPS IVA is detected in 95% of individuals impacted by MPS IV while MPS IVB is detected in around 5% of affected individuals.
Morquio Syndrome Therapy Market Geographical Share
North America is Expected to Dominate the Global Market
Owing to the increase research initiatives and funding are expected to boost the North American market, dominating the global market during the forecast period. For instance, in May 2023, as a component of the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC), Nemours Children's Health has been picked to execute a first-of-its-kind gene therapy clinical trial for Morquio A syndrome.
Again, in August 2023, a unique initiative strives to eliminate hindrance, delivering $97 million in funds and expertise to assist investigators in testing gene therapy in individuals with Morquio and seven other ultrarare diseases as soon as next year. The program, a coalition of nonprofits, government, and industry, is directed by the non-profit Foundation for the National Institutes of Health. Furthermore, the growing awareness and prevalence of the condition is also contributing to the regional market growth during the forecast period.
COVID-19 Impact Analysis
Enzyme replacement therapy (ERT) is a common treatment for certain types of lysosomal storage diseases (LSDs), which involves intravenously administering weekly or biweekly doses. ERT has been found to improve respiratory and cardiac function, alleviate organomegaly, improve range of motion, and enhance the overall health-related quality of life for some types of mucopolysaccharidoses (MPS).
However, the global market growth for scheduled ERT was negatively affected due to COVID-19 disruptions. Lysosomal storage diseases are high-risk illnesses because of their involvement with respiratory, renal, and cardiac functions. The COVID-19 pandemic has also disrupted the availability of ERT, which has had a significant impact on the global market growth.
Key Developments
June 2026: BioMarin continued strengthening the clinical evidence base for VIMIZIM (elosulfase alfa), the enzyme replacement therapy indicated for patients with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). Current clinical information continues to highlight sustained improvements in endurance and pulmonary function with long-term treatment, reinforcing ERT as a key therapeutic approach for Morquio A.
May 2026: BioMarin continued supporting the long-term clinical use of VIMIZIM, with updated healthcare-professional resources emphasizing its efficacy across multiple disease manifestations. Long-term extension data have demonstrated sustained effects on endurance, while pulmonary-function analyses indicate maintained respiratory function in treated patients.
April 2026: The Morquio A Registry Study (MARS) continued contributing real-world evidence on the natural history and long-term management of MPS IVA. The multinational observational program follows patients with confirmed MPS IVA and evaluates disease characteristics alongside the long-term effectiveness and safety of elosulfase alfa therapy, supporting evidence-based management of this ultra-rare disorder.
March 2026: VIMIZIM (elosulfase alfa) remained the established enzyme replacement therapy for Morquio A syndrome, with ongoing clinical evidence supporting its role in addressing progressive functional impairment. Long-term studies have reported sustained endurance outcomes, while clinical data continue to support monitoring of respiratory function and other multisystem manifestations during treatment.
February 2026: The Morquio syndrome treatment landscape continued to focus on early diagnosis, long-term enzyme replacement therapy, and comprehensive multisystem management. Because Morquio A is a progressive condition affecting skeletal, respiratory, mobility, and other organ systems, continued clinical monitoring and long-term treatment remain central to disease management.
Morquio Syndrome Therapy Market Major Players
The major global players in the market include BioMarin, JCR Pharmaceuticals Co., Ltd., Novartis AG, Takeda Pharmaceutical Company Limited., Alexion Pharmaceuticals, Inc., Regenxbio Inc., Ultragenyx Pharmaceutical Inc., Abbvie Inc., and Abeona Therapeutics Inc. among others.
Why Purchase the Report?
- To visualize the global morquio syndrome therapy market segmentation based on type, therapy, route of administration, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of morquio syndrome therapy market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global morquio syndrome therapy market report would provide approximately 69 tables, 67 figures and 192 pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
